A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054 · EMBER-4 Phase 3Active, not recruiting
- Lead sponsor
- Eli Lilly and Company (Industry)
- Enrollment
- 8,000 (estimated)
- Start date
- 4 Oct 2022
- Primary completion
- Oct 2027 (estimated)
- Study completion
- 1 Mar 2032
- Last update posted
- 2 Apr 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- Imlunestrant Drug
- Tamoxifen Drug
- Anastrozole Drug
- Letrozole Drug
- Exemestane Drug
Conditions and primary outcome
- Breast Neoplasms
Primary outcome
Invasive Disease-Free Survival (IDFS) (Randomization to recurrence or death from any cause (up to 10 years))
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT05514054.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT05514054 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.